14th edition

Format
HYBRID

December 2nd & 3rd, 2025

IN-PERSON | STRASBOURG

December 8th ,2025

ONLINE MEETINGS

14th edition

Format
HYBRID

December 2nd & 3rd, 2025

IN-PERSON | STRASBOURG

December 8th ,2025

ONLINE MEETINGS

Thinking of the exit scenario to shape a biotech start-up at its first steps: Which model for which term of exit?

Thinking of the exit scenario to shape a biotech start-up at its first steps: Which model for which term of exit?

When creating a biotech start-up, different routes can be taken: the virtual biotech model, the technology platform model, the one single asset company… How do those initial choices influence the exit scenario of the company?

Mark Krul

Partner
The Netherlands
Aglaia BioMedical Ventures

Lucie Ellis

Managing Editor
United Kingdom
In Vivo Pharma Intelligence | Informa

Rodolphe Besserve

Head SuFT Advisory, Start-ups & French Techs
France
Société Générale Corporate Investments and Banking

George Hoffmann

Co-founder and CEO
Canada
Network Immunology

Peter Leonardi

CEO
USA
OmniCyte
Scroll to Top
  • No products in the cart.